Sectoral Asset Management Inc. Has $647,000 Stock Position in BioMarin Pharmaceutical Inc. $BMRN

Sectoral Asset Management Inc. decreased its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 56.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 10,880 shares of the biotechnology company’s stock after selling 14,150 shares during the quarter. Sectoral Asset Management Inc.’s holdings in BioMarin Pharmaceutical were worth $647,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the stock. Northwestern Mutual Investment Management Company LLC increased its position in shares of BioMarin Pharmaceutical by 0.4% during the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 42,982 shares of the biotechnology company’s stock worth $2,554,000 after purchasing an additional 183 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in shares of BioMarin Pharmaceutical by 7.7% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,741 shares of the biotechnology company’s stock worth $163,000 after acquiring an additional 195 shares during the period. EverSource Wealth Advisors LLC boosted its stake in shares of BioMarin Pharmaceutical by 3.4% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 7,151 shares of the biotechnology company’s stock worth $387,000 after acquiring an additional 235 shares during the period. Davis Investment Partners LLC boosted its stake in shares of BioMarin Pharmaceutical by 3.1% during the 4th quarter. Davis Investment Partners LLC now owns 8,031 shares of the biotechnology company’s stock worth $477,000 after acquiring an additional 243 shares during the period. Finally, Parallel Advisors LLC boosted its stake in shares of BioMarin Pharmaceutical by 62.2% during the 3rd quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 295 shares during the period. Institutional investors and hedge funds own 98.71% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on BMRN shares. Wolfe Research reiterated an “outperform” rating on shares of BioMarin Pharmaceutical in a research note on Monday, March 16th. Jefferies Financial Group reiterated a “buy” rating and set a $103.00 target price on shares of BioMarin Pharmaceutical in a research note on Thursday, March 12th. Oppenheimer reduced their target price on BioMarin Pharmaceutical from $98.00 to $95.00 and set an “outperform” rating for the company in a research note on Tuesday, February 24th. Wells Fargo & Company lifted their target price on BioMarin Pharmaceutical from $70.00 to $75.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 18th. Finally, Truist Financial upgraded BioMarin Pharmaceutical to a “strong-buy” rating in a research note on Wednesday, March 25th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, BioMarin Pharmaceutical has an average rating of “Moderate Buy” and a consensus target price of $88.67.

BioMarin Pharmaceutical Stock Performance

BMRN opened at $54.09 on Monday. The business has a fifty day simple moving average of $54.56 and a 200 day simple moving average of $56.27. The company has a market capitalization of $10.45 billion, a PE ratio of 39.48, a price-to-earnings-growth ratio of 0.41 and a beta of 0.23. BioMarin Pharmaceutical Inc. has a 1 year low of $49.26 and a 1 year high of $66.28. The company has a debt-to-equity ratio of 0.23, a current ratio of 5.81 and a quick ratio of 4.20.

Key Headlines Impacting BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BioMarin said Voxzogo met its main goal in a late-stage hypochondroplasia study, supporting plans to file with the FDA in 2026 and boosting investor optimism about another potential growth driver. Article Title
• Positive Sentiment: Analyst commentary remained constructive overall, with Canaccord Genuity cutting its price target to $111 from $116 but reiterating a buy rating, implying substantial upside from current levels. Article Title
• Neutral Sentiment: Several press items from The Globe and Mail and TipRanks highlighted additional analyst coverage on BMRN, but they did not add a clear new operating catalyst beyond general sentiment and valuation commentary. Article Title
• Neutral Sentiment: BioMarin’s Phase 3 ENERGY 3 trial of BMN 401 met one co-primary endpoint but missed the other, making the readout mixed rather than clearly successful. Article Title
• Negative Sentiment: The mixed BMN 401 results triggered a notable selloff, with investors reacting to uncertainty around the drug’s commercial prospects and the likelihood of a clean regulatory path. Article Title

Insider Buying and Selling at BioMarin Pharmaceutical

In related news, EVP Charles Greg Guyer sold 16,486 shares of the business’s stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $60.46, for a total value of $996,743.56. Following the completion of the sale, the executive vice president directly owned 79,953 shares in the company, valued at $4,833,958.38. The trade was a 17.09% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Gregory R. Friberg sold 3,281 shares of the business’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $53.85, for a total value of $176,681.85. Following the completion of the sale, the executive vice president owned 51,818 shares of the company’s stock, valued at $2,790,399.30. This trade represents a 5.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 26,093 shares of company stock valued at $1,555,389 over the last 90 days. 0.85% of the stock is currently owned by corporate insiders.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.